| Serial Number | 79444386 |
| Word Mark | MYRICX |
| Filing Date | Wednesday, August 6, 2025 |
| Status | 641 - NON-FINAL ACTION - MAILED |
| Status Date | Saturday, July 4, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Pharmaceutical and biotechnological preparations; pharmaceutical and biotechnological preparations for the diagnosis and treatment of human diseases; pharmaceutical and biotechnological preparations for the diagnosis and treatment of proliferative human diseases; pharmaceutical and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; antibody drug conjugates (ADCs); antibody drug conjugates (ADCs) for the diagnosis and treatment of human diseases; antibody drug conjugates (ADCs) for the diagnosis and treatment of proliferative human diseases; antibody drug conjugates (ADCs) for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; N-myristoyltransferases (NMT) inhibitors; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treatment of human diseases; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treatment of proliferative human diseases; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging. |
| Goods and Services | Commercialisation of pharmaceuticals and biotechnological preparations; commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of human diseases; commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of proliferative human diseases; commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; commercialisation of antibody drug conjugates (ADCs) and N-myristoyltransferases (NMT) inhibitors; consultancy, advisory and information services relating to the aforesaid services. |
| Goods and Services | Scientific and biomedical research; scientific and biomedical research in the field of human diseases; scientific and biomedical research in the field of proliferative human diseases; scientific and biomedical research in the field of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; development and testing of pharmaceuticals and biotechnological preparations; scientific and technological research, development and testing of pharmaceuticals and biotechnological preparations, including scientific and technological research for their commercialisation; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of human diseases; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of human diseases, and scientific and technological research supporting their commercialisation; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of proliferative human diseases; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of proliferative human diseases, and scientific and technological research supporting their commercialisation; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence, and diseases of aging, and scientific and technological research supporting their commercialisation; development and testing of antibody drug conjugates (ADCs) and N-myristoyltransferases (NMT) inhibitors; development and testing of antibody-drug conjugates (ADCs) and N-myristoyltransferase (NMT) inhibitors, and scientific and technological research supporting their commercialisation; consultancy, advisory and information services relating to the aforesaid services. |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, February 26, 2026 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 035 - Advertising; business management; business administration; office functions. |
| US Class Codes | 100, 101, 102 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, May 1, 2026 |
| Primary Code | 035 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, February 26, 2026 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Myricx Pharma Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Event Date | Event Description |
| Thursday, February 26, 2026 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, February 27, 2026 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, February 27, 2026 | APPLICATION FILING RECEIPT MAILED |
| Saturday, February 28, 2026 | ASSIGNED TO EXAMINER |
| Tuesday, March 3, 2026 | NON-FINAL ACTION WRITTEN |
| Wednesday, March 4, 2026 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Thursday, March 26, 2026 | CORRECTION TRANSACTION RECEIVED FROM IB |
| Friday, May 1, 2026 | CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED |
| Sunday, May 3, 2026 | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW |
| Wednesday, May 13, 2026 | NON-FINAL ACTION WRITTEN |
| Thursday, May 14, 2026 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Saturday, July 4, 2026 | REFUSAL PROCESSED BY MPU |
| Saturday, July 4, 2026 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |